Chen Dongshan, Zhang Chen, Zang Yuanwei, Wang Wei, Zhang Jiandong
Department of Urology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Taiyuan, China.
Department of Urology, Tongji Hospital, Tongji Medical College, Wuhan, China.
Front Genet. 2022 Aug 29;13:970900. doi: 10.3389/fgene.2022.970900. eCollection 2022.
Despite considerable progress has been made in the understanding of the genetics and molecular biology of renal cell carcinoma (RCC), therapeutic options of patients with papillary renal cell carcinoma (PRCC) are limited. Immunotherapy based on immune checkpoint inhibitors (ICIs) has become a hot point in researching new drug for tumor and been tested in a number of human clinical trials. In this study, an immune-related gene prognostic index (IRGPI) was developed and provided a comprehensive and systematic analysis of distinct phenotypic and molecular portraits in the recognition, surveillance, and prognosis of PRCC. The reliability of the IRGPI was evaluated using independent datasets from GEO database and the expression levels of the genes in the IRGPI detected by real-time PCR. Collectively, the currently established IRGPI could be used as a potential biomarker to evaluate the response and efficacy of immunotherapy in PRCC.
尽管在肾细胞癌（RCC）的遗传学和分子生物学理解方面取得了相当大的进展，但乳头状肾细胞癌（PRCC）患者的治疗选择仍然有限。基于免疫检查点抑制剂（ICIs）的免疫疗法已成为肿瘤新药研究的热点，并已在多项人体临床试验中进行了测试。在本研究中，开发了一种免疫相关基因预后指数（IRGPI），并对PRCC的识别、监测和预后中的不同表型和分子特征进行了全面系统的分析。使用来自GEO数据库的独立数据集评估IRGPI的可靠性，并通过实时PCR检测IRGPI中基因的表达水平。总体而言，目前建立的IRGPI可作为评估PRCC免疫治疗反应和疗效的潜在生物标志物。
